众安保险将国内首款干细胞治疗药品纳入赔付范围

Core Insights - The first domestically approved stem cell therapy drug, Aimi Maitosai injection, has been prescribed for the first time in China [1] - ZhongAn Insurance, as a strategic partner of Albo Bio, includes the Aimi Maitosai injection in its health insurance products, with a maximum reimbursement rate of 100% for eligible claims [1] Company Summary - ZhongAn Insurance has integrated the Aimi Maitosai injection into its core health insurance product lines, including Zunxiang Esheng and Zhongminbao [1] - The inclusion of this stem cell therapy in the insurance coverage represents a significant development in the health insurance sector in China [1] Industry Summary - The approval and prescription of the Aimi Maitosai injection mark a milestone in the stem cell therapy market in China, potentially opening new avenues for treatment and insurance coverage [1] - The collaboration between ZhongAn Insurance and Albo Bio highlights the growing intersection of biotechnology and health insurance, indicating a trend towards more comprehensive coverage for advanced medical treatments [1]